Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
BMC Cancer|June 9, 2019
Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims databaseSumanta Pal, Jun Gong, Shivani K Mhatre, et al.
Clinical Colorectal Cancer|June 17, 2017
Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line TherapyStephen Johnston, Kathleen Wilson, Helen Varker, et al.
The Oncologist|August 3, 2014
Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancerVeena Shankaran, David Mummy, Lisel Koepl, et al.
The American Journal of Managed Care|June 18, 2020
Claims identification of patients with severe cancer-related symptomsRichard W DeClue, Dana Drzayich Antol, Adrianne W Casebeer, et al.
Bladder Cancer (Amsterdam, Netherlands)|May 8, 2018
Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United StatesMatthew D Galsky, Sumanta Kumar Pal, Shih-Wen Lin, et al.
The Oncologist|February 28, 2019
Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's LymphomaCarolina Reyes, Nicole M Engel-Nitz, Stacey DaCosta Byfield, et al.
The Oncologist|February 24, 2019
Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal CancerCarolina Reyes, Nicole M Engel-Nitz, Stacey DaCosta Byfield, et al.
Targeted Oncology|June 21, 2023
ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort StudyMichelle Wang, Shadera Slatter, Jesse Sussell, et al.
Cancers|October 26, 2024
Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration DatabaseDavid E Kaplan, Ruoding Tan, Cheryl Xiang, et al.
American Journal of Clinical Oncology|October 9, 2025
A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United StatesAmy L Cummings, Jesse Sussell, Katherine L Rosettie, et al.
Pageof 5